ngµç×ÓÓÎÏ·

03
Ê×Ò³ / ½Ìѧ¿ÆÑÐ / ÕýÎÄ

¸ß¹úÈ«ÍŶÓÕ¹ÏַǾƾ«ÐÔÖ¬·¾¸Î²¡±¬·¢¿ªÕ¹ºÍ°¢¶û×Ⱥ£Ä¬²¡µÄÒªº¦µ÷¿Ø·Ö×Ó

¸å¼þȪԴ£º£ºÖÐɽҽѧԺ ±à¼­£º£ºÂ¬ì½Î¬ ÉóºË£º£ºËïÒ«±ó ÔĶÁÁ¿£º£º

ngµç×ÓÓÎÏ·ÐÂÎÅÍøÑ¶£¨Í¨Ñ¶Ô±Æëì¿ì¿ ¡¢·½ÕäÕ䣩Kallistatin£¨KAL£©£¬£¬ÓÉSERPINA4±àÂ룬£¬ÊÇÖ÷Òª±í´ïÔÚ¸Îϸ°ûÖеÄÉøÍ¸ÂѰס£¡£¸ß¹úÈ«½ÌÊÚÍŶӺã¾Ã´ÓÊÂÌÇÄò²¡ ¡¢Ö×Áö´úлÓ벡ÀíÐÔѪ¹ÜÐÂÉúÒªº¦µ÷¿Ø·Ö×ӵĻúÖÆÑо¿£¬£¬ÒÔÍùµÄÑо¿Ö¤ÊµÎúÌÇÄò²¡»¼ÕßÍâÖÜѪÖеÄKALˮƽÏÔ×ÅÉý¸ß£¬£¬¿ÉÒÔ¼¤»îºËÒò×Ó¦ÊB£¨NF-¦ÊB£©ÐźÅͨ·£¬£¬µ¼ÖÂÌÇÄò²¡ÉË¿Ú×éÖ¯µÄÑ×Ö¢¡£¡£ÏÖÔÚÍŶÓÔÚ¸ÃÑо¿ÁìÓòÈ¡µÃÁËеÄÏ£Íû£º£º

·Ç¾Æ¾«ÐÔÖ¬·¾¸Î²¡£¡£¨Non-alcoholic fatty liver disease£¬£¬NAFLD£©ÊÇһϵÁиÎÔàÏà¹Ø¼²²¡µÄ×ܳÆ£¬£¬°üÀ¨¸ÎÖ¬·¾±äÐÔ ¡¢·Ç¾Æ¾«ÐÔÖ¬·¾ÐÔ¸ÎÑ×£¨NASH£©ºÍ¸ÎÓ²»¯µÈ¸ÎÔ༲²¡£¬£¬È«ÇòNAFLDµÄ»¼²¡Âʸߴï25%¡£¡£ÔÚÑÇÖÞÓкܴó±ÈÀýµÄNAFLD²¡È˲¢²»·ÊÅÖ£¬£¬ÎÄÏ×±¨µÀ£¬£¬·Ç·ÊÅÖÐ͵ÄNAFLD²¡È˸ÊÓÍÈýõ¥Ë®Æ½Í¨³£¸ü¸ß£»£»£»¸ß֬Ѫ֢£¬£¬ÌØÊâÊǸ߸ÊÓÍÈýõ¥ÑªÖ¢£¬£¬ÊÇNAFLDµÄ×ÔÁ¦Î£ÏÕÒòËØ¡£¡£¿ÉÊǽ鵼¸ß֬Ѫ֢ºÍNAFLDÀú³ÌµÄÒªº¦µ÷¿Ø·Ö×ÓÉв»Ã÷È·¡£¡£

2024Äê3ÔÂ12ÈÕ£¬£¬ngµç×ÓÓÎÏ·ÖÐɽҽѧԺ¸ß¹úÈ« ¡¢ÖÜÙà ¡¢Ñîϼ½ÌÊÚÍŶÓÔÚSignal Transduction and Targeted TherapyÉϽÒÏþÁËÌâΪ¡°Elevated Kallistatin promotes the occurrence and progression of non-alcoholic fatty liver disease¡±µÄÑо¿ÂÛÎÄ¡£¡£¸ÃÑо¿»ùÓÚÊý¾Ý¿âÆÊÎö ¡¢ÁÙ´²ÑùÌìÖ°Îö ¡¢×ª»ùÒòСÊóÄ£×ÓºÍת¼×éѧÑо¿µÈ£¬£¬Ö¤ÊµÎúHTGÖÐÒì³£Éý¸ßµÄ¸ÎÉøÍ¸Òò×ÓKALͨ¹ý°ÐÏòCGI-58/NF-¦ÊB/TNF-¦ÁÐźÅͨ·¼ÓÈëµ÷¿ØNAFLDµÄ±¬·¢ºÍ¿ªÕ¹¡£¡£¸ÃÑо¿Ã÷È·Á˽鵼¸ß֬Ѫ֢ÏòNAFLD¿ªÕ¹µÄÒªº¦µ÷¿Ø·Ö×Ó£¬£¬ÆÊÎöÁËKALͨ¹ýLRP6/PKA/GSK3¦ÂÐźÅͨ·Ïµ÷TGË®½âµÄÒªº¦Ã¸ATGL¼°Æä¹²¼¤»îÒò×ÓCGI-58µ¼Ö¸ÎÖ¬·¾±äÐÔ£¬£¬Ïµ÷µÄCGI-58ͨ¹ý·ÇATGLÒÀÀµµÄ;¾¶¼¤»îNF-¦ÊB p65/TNF¦ÁÑ×֢ͨ·Ôö½øNASHµÄ±¬·¢£¬£¬Í¬Ê±Õ¹ÏÖÁËHTGÖÐKALÉϵ÷µÄ»úÖÆ¡£¡£ÕâЩ·¢Ã÷Ϊ×è¶Ï¸ß֬Ѫ֢ÏòÖ¬·¾±äÐÔ¼°NASHÏ£ÍûÌṩÁËÐÂ˼Ð÷ºÍае㣬£¬±¾Ñо¿¾Û½¹Öйú³£¼ûµÄ·Ç·ÊÅÖÐÍNAFLDÈËȺ£¬£¬¾ßÓнÏÇ¿µÄÁÙ´²¼ÛÖµ¡£¡£×¨Ö°¿ÆÑÐÖ°Ô±·½ÕäÕ丱Ñо¿Ô±ÎªÂÛÎĵĵÚÒ»×÷Õß¡£¡£

7404B9BB8DA7725E32EAC2B4587_723F7FE4_6AE4C

°¢¶û´Äº£Ä¬²¡£¡£¨Alzheimer's disease£¬£¬AD£©ÊÇÒ»ÖÖ¾ÙÐÐÐÔÉñ¾­ÍËÐÐÐÔ¼²²¡£¬£¬Ò²ÊÇÒ»Öָ߶ÈÒìÖÊÐÔµÄÐàÂõÏà¹Ø¼²²¡£¬£¬ÊÇÈÏÖª¹¦Ð§Ï½µ×î³£¼ûµÄÔ­Òò¡£¡£Ëæ×ÅÉú³ÝÀÏÁ仯ÎÊÌâµÄÖ𽥼Ӿ磬£¬ADÒÑÈ»³ÉΪһ¸öÈ«Çò¹«¹²ÎÀÉúÎÊÌ⣬£¬Òò´Ë¶ÔADµÄ·¢²¡Ô­ÒòºÍÖÎÁưеãµÄÑо¿Ò»Ö±ÊÇÉñ¾­¿ÆÑ§ÁìÓòµÄÈÈÃźÍÄѵã¡£¡£Ô½À´Ô½¶àµÄ±¨µÀÅú×¢´úлÔÓÂÒºÍAD»¼ÕßÈÏÖªÕϰ­Ö®¼ä±£´æÇ×½ü¹ØÏµ¡£¡£ÌÇÄò²¡ ¡¢¸ß֬Ѫ֢¼°·ÊÅÖ¾ùΪADµÄ¸ß·çÏÕÒòËØ¡£¡£

2024Äê3ÔÂ14ÈÕ£¬£¬ngµç×ÓÓÎÏ·ÖÐɽҽѧԺÆëì¿ì¿ ¡¢¸ß¹úÈ« ¡¢Ñîϼ½ÌÊÚÍŶÓÔÚPharmacological ResearchÉϽÒÏþÁËÌâΪ¡°Kallistatin leads to cognition impairment via downregulating glutamine synthetase¡±µÄÑо¿ÂÛÎÄ¡£¡£¸ÃÑо¿»ùÓÚGEOÊý¾Ý¿â ¡¢ÁÙ´²ÑùÌìÖ°Îö ¡¢×ª»ùÒòСÊóÄ£×ÓÑéÖ¤µÈ£¬£¬Ö¤ÊµÎúAD»¼ÕßѪÇåÖÐKallistatinº¬Á¿ÏÔÖøÔö¶à£»£»£»Ã÷È·ÁËKAL-TGСÊó·ºÆðÓ°ÏóÈÏÖª¹¦Ð§ ¡¢º£ÂíÍ»´¥¿ÉËÜÐÔϽµ¼°¹È°±ËáÎÈ̬ʧºâ£¬£¬Ö¤Êµ¹ý±í´ïkallistatinͨ¹ýÆÆËð¹È°±Ëá-¹È°±õ£°·Ñ­»·ÓÕ·¢¹È°±ËáÐË·ÜÐÔ¶¾ÐÔ£»£»£»·Ö×ÓˮƽÉÏ£¬£¬·¢Ã÷Kallistatinͨ¹ýµ÷Àí¹È°±õ£°·ºÏ³Éø£¨GS£©µÄÒÒõ£»£»£»¯-·ºËØ»¯ÐÞÊÎÀ´Ôö½øÆä½µ½â¡£¡£GS¼¤¶¯¼Á¿ÉÒÔÓÐÓøÄÉÆKAL-TGСÊóµÄÍ»´¥¿ÉËÜÐÔ¼°Ó°ÏóÈÏÖª¹¦Ð§£»£»£»¹Å°å½µÖ¬Ò©Îï·Çŵ±´ÌؾßÓÐϵ÷Kallistatin ¡¢Éϵ÷GS£¬£¬ÑÓ»ºÐ¡ÊóÓ°ÏóÈÏÖª¹¦Ð§Ï½µµÄЧ¹û¡£¡£±¾Ñо¿ÎªÁÙ´²ÉÏÔçÆÚÔ¤·ÀºÍÖÎÁÆADÌṩÁËеÄÀíÂÛÒÀ¾ÝºÍ¸ÉÔ¤°Ðµã¡£¡£

40C61B0E43128957045C3DD21EE_D8A11B9E_FE50

ÒÔÉÏÑо¿»ñµÃ¿Æ¼¼²¿¹ú¼ÒÖØµãÑз¢ÍýÏë ¡¢¹ú¼Ò×ÔÈ»¿ÆÑ§»ù½ðίµÈÏîÄ¿×ÊÖú¡£¡£¸ÃÑо¿Ó뽯±ó½ÌÊÚÍŶÓÏàÖú£¬£¬ÀÐ˽ÌÊÚÌṩָµ¼×ÊÖú£¬£¬»ñµÃngµç×ÓÓÎϷʵÑ鶯ÎïÖÐÐÄ ¡¢Ò½¿Æ¹«¹²Æ½Ì¨£¨¹ãÖÝÐ£Çø£©µÄ´óÁ¦Ö§³Ö¡£¡£

Ô­ÎÄÁ´½Ó£º£º

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10933339/

https://pubmed.ncbi.nlm.nih.gov/38492829/

¡¾ÍøÕ¾µØÍ¼¡¿